NCCM
BLRX

Nine Chapters Capital Management’s BioLineRX BLRX Stock Holding History

Nine Chapters Capital Management’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-100
Closed -$92K – 78
2015
Q3 		$92K Sell
100
-117
-54% -$125K 0.01% 919
2015
Q2 		$347K Buy
+217
New +$269K 0.03% 684

Other funds holding BLRX

SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
MC
Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Nine Chapters Capital Management's BLRX Position: Q4 2015 in Review

Nine Chapters Capital Management sold out of BioLineRX (BLRX) in Q4 2015, closing a stake of 100 shares — an estimated $92K sold.

Nine Chapters Capital Management first reported a position in BLRX in Q2 2015 and held it in 2 quarters. The position peaked at $347K in Q2 2015. 23 funds tracked by Wall St. Rank hold BLRX as of Q4 2015.

  • Nine Chapters Capital Management reported no remaining BioLineRX position as of Q4 2015 after selling out during the quarter.
  • Nine Chapters Capital Management sold 100 BioLineRX shares in Q4 2015, an estimated $92K.
  • Nine Chapters Capital Management first reported a position in BioLineRX in Q2 2015 and held it in 2 quarters.
  • Nine Chapters Capital Management's BioLineRX position peaked at $347K in Q2 2015.
  • 23 funds tracked by Wall St. Rank held BioLineRX as of Q4 2015.

Based on Nine Chapters Capital Management's 13F filing for Q4 2015.